| Literature DB >> 36262270 |
Lou'i Al-Husinat1, Mokeem Nusir1, Haitham Al-Gharaibeh1, Amer A Alomari2, Mahmoud M Smadi3, Denise Battaglini4, Paolo Pelosi4,5.
Abstract
Background: Post-COVID-19 Syndrome (PCS) is characterized by residual symptoms following the initial recovery from severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. The prevalence of PCS is known to be the highest among severe and critical forms of the disease. However, the occurrence and risk factors for PCS after mild or moderate SARS-CoV-2 infection has not been extensively investigated.Entities:
Keywords: SARS-CoV-2 infection; chronic COVID-19 syndrome; mood disturbance; post-COVID-19 syndrome; post-acute sequelae of SARS-CoV-2 infection
Year: 2022 PMID: 36262270 PMCID: PMC9573938 DOI: 10.3389/fmed.2022.1017257
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
The prevalence of PCS symptoms in the overall population.
| Post-COVID-19 symptoms | Prevalence population | Prevalence of PCS according to gender | Prevalence of PCS according to age | ||||
| Female | Male | Age < 30 years | Age ≥ 30 years | ||||
| Mood disturbance/depression | 294, 59.4% | 204 (62%) | 90 (54%) | 0.059 | 126 (61%) | 168 (58%) | 0.579 |
| Fatigue | 279, 56.4% | 201 (61%) | 78 (47%) |
| 123 (59%) | 156 (54%) | 0.271 |
| Anxiety | 234, 47.3% | 167 (51%) | 67 (40%) |
| 104 (50%) | 130 (45%) | 0.274 |
| Myalgia | 209, 42.2% | 153 (47%) | 56 (51%) |
| 106 (51%) | 103 (36%) |
|
| Sleep disturbance | 203, 41.1% | 141 (43%) | 62 (37%) | 0.246 | 83 (40%) | 120 (42%) | 0.781 |
| Change in smell | 202, 40.8% | 156 (50%) | 46 (30%) |
| 77 (37%) | 125 (47%) | 0.524 |
| Palpitation | 182, 36.8% | 133 (40%) | 49 (30%) |
| 76 (38%) | 106 (37%) | 1.00 |
| Residual symptoms | 168, 33.9% | 126 (38%) | 42 (13%) |
| 72 (35%) | 96 (33%) | 0.773 |
| Weakness | 161, 32.5% | 121 (36%) | 40 (24%) |
| 78 (38%) | 83 (29%) |
|
| Nightmares/flashbacks | 138, 27.9% | 95 (29%) | 43 (26%) | 0.525 | 51 (25%) | 87 (30%) | 0.817 |
| Shortness of breath | 138, 27.9% | 110 (33%) | 28 (17%) |
| 57 (28%) | 81 (28%) | 0.919 |
| Weight loss | 135, 27.3% | 94 (29%) | 41 (33%) | 0.393 | 63 (30%) | 72 (25%) | 0.185 |
| Loss of smell sensation | 73, 14.7% | 55 (17%) | 18 (12%) | 0.107 | 33 (16%) | 40 (14%) | 0.089 |
| Cough | 69, 13.9% | 49 (15%) | 20 (12%) | 0.413 | 28 (14%) | 41 (14%) | 0.896 |
| Loss of taste sensation | 26, 5.3% | 21 (6%) | 5 (3%) | 0.137 | 11 (5%) | 15 (5%) | 1.00 |
Bold values mean significant association with age/gender.
FIGURE 1Flow chart of inclusion/exclusion process.
FIGURE 2Clustered bar chart of different Post-COVID-19 Syndrome (PCS) symptoms according to gender (left chart) and age (right chart).
Analysis of the association between different symptoms with gender and age.
| Outcome | Age | Gender | ||||
| OR | 95% CI | OR | 95% CI | |||
| Mood disturbance/depression | 0.998 | 0.982–1.015 | 0.818 | 1.380 | 0.940–2.003 | 0.095 |
| Fatigue | 1.003 | 0.986–1.020 | 0.732 | 1.768 | 1.213–2.578 |
|
| Anxiety | 0.992 | 0.976–1.008 | 0.319 | 1.533 | 1.050–2.238 |
|
| Change in smell | 0.979 | 0.962–0.997 |
| 2.355 | 1.559–3.560 |
|
| Myalgia | 1.029 | 1.012–1.046 |
| 1.691 | 1.143–2.503 |
|
| Sleep disturbance | 0.992 | 0.975–1.008 | 0.318 | 1.272 | 0.865–1.862 | 0.218 |
| Palpitation | 0.990 | 0.973–1.007 | 0.243 | 1.633 | 1.088–2.421 |
|
| Residual symptoms | 0.993 | 0.975–1.010 | 0.405 | 1.843 | 1.209–2.771 |
|
| Weakness | 1.016 | 0.998–1.033 | 0.075 | 1.817 | 1.192–2.770 |
|
| Nightmares/flashbacks | 0.986 | 0.967–1.005 | 0.139 | 1.172 | 0.771–1.796 | 0.462 |
| Shortness of breath | 0.995 | 0.977–1.014 | 0.621 | 2.484 | 1.558–3.961 |
|
| Weight loss (>3 Kg) | 1.004 | 0.986–1.022 | 0.679 | 1.216 | 0.787–1859 | 0.368 |
| Loss of smell sensation | 0.996 | 0.973–1.019 | 0.714 | 1.655 | 0.929–2.899 | 0.082 |
| Cough | 0.992 | 0.969–1.017 | 0.533 | 1.284 | 0.734–2.239 | 0.380 |
| Loss of taste sensation | 0.998 | 0.962–1.035 | 0.906 | 2.199 | 0.813–5.938 | 0.120 |
CI, confidence interval; OR, Odds Ratio. Bold values mean significant association with age/gender.